Multicentre, Randomized, Multi-arm Trial Comparing the Efficacy and Safety of Adalimumab, Anakinra and Tocilizumab in Subjects With Non-infectious Refractory Uveitis RUBI: Refractory Uveitis BIotherapies
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Anakinra (Primary) ; Tocilizumab (Primary) ; Adalimumab
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms RUBI
- 25 Jun 2024 Status changed from recruiting to completed.
- 04 Jul 2017 Status changed from not yet recruiting to recruiting.
- 09 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.